Stockscreener 앱 받기
2.08
8.90%
0.17
시간 외 거래:
3.18
1.10
+52.88%
Sunshine Biopharma Inc 주식(SBFM)의 최신 뉴스
Sunshine Biopharma (SBFM) Reports 2024 Financial Highlights - GuruFocus
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year - ACCESS Newswire
Sunshine Biopharma Reports Record Revenue: 13 New Drugs and Cancer Treatment Breakthrough - Stock Titan
Sunshine Biopharma Inc. SEC 10-K Report - TradingView
Sunshine Biopharma Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Sunshine Biopharma signs agreement for rights to market two generic antibiotics - Yahoo Finance
Sunshine Biopharma to market new antibiotics in Canada By Investing.com - Investing.com Australia
Sunshine Biopharma acquires marketing rights for two new antibiotics in Canada - MSN
Sunshine Biopharma to market new antibiotics in Canada - Investing.com India
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada - Yahoo Finance
Major Antibiotics Deal: Sunshine Biopharma Expands Portfolio in Billion-Dollar Market - Stock Titan
Sunshine Biopharma stock hits 52-week low at $2.01 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.01 - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 0.5% – Should You Sell? - Defense World
Sunshine Biopharma expands with new gastrointestinal drug By Investing.com - Investing.com Canada
Sunshine Biopharma expands with new gastrointestinal drug - Investing.com India
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - ACCESS Newswire
Sunshine Biopharma Launches First of Two New Gastrointestinal Drugs in Canada - Stock Titan
Sunshine Biopharma stock hits 52-week low at $2.09 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.09 - Investing.com India
A Look at Sunshine Biopharma Inc (SBFM) Shares in the Recent Past Indicates Growth - SETE News
Sunshine Biopharma (NASDAQ:SBFMW) Trading 30% Higher – Should You Buy? - Defense World
Sunshine Biopharma Announces Reverse Stock Split - ACCESS Newswire
Sunshine Biopharma Launches Two New Generic Prescription Drugs - ACCESS Newswire
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) - ACCESS Newswire
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% - ACCESS Newswire
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Who’s Hired? Haruvi Returns For A Second Term As AAM Chair - News & Insights
Sunshine Biopharma launches Olanzapine and Olanzapine ODT - Indian Pharma Post
Sunshine Biopharma introduces new generic drugs in Canada - MSN
Sunshine Biopharma Appoints New Chief Commercial Officer - MSN
Sunshine Biopharma Launches Generic Mental Health Drug in Rapidly Growing Canadian Market - StockTitan
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT - Yahoo Finance
Sunshine Biopharma Appoints Michel Roy as Chief Commercial Officer - Defense World
Sunshine Biopharma appoints Michel Roy as CCO - MSN
Sunshine Biopharma names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Sunshine Biopharma names new Chief Commercial Officer - Investing.com
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer - WICZ
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 14.6% in December - Defense World
Sunshine Biopharma Inc. Elects New Directors and Ratifies Appointment of Independent Registered Public Accounting Firm - Defense World
Sunshine Biopharma re-elects board, ratifies CPA firm By Investing.com - Investing.com Nigeria
Sunshine Biopharma re-elects board, ratifies CPA firm - Investing.com India
Sunshine Biopharma’s PLpro inhibitor shows activity in SARS-CoV-2 - BioWorld Online
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus - AccessWire
Sunshine Biopharma's Novel COVID-19 Oral Treatment Shows Breakthrough Antiviral Activity in Preclinical Study - StockTitan
Sunshine Biopharma Launches a New Generic Prescription Drug - AccessWire
1.48%
0.34%
자본화:
|
볼륨(24시간):